Et al Phillip Frost MD - 04 Apr 2023 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Role
Director, 10%+ Owner
Signature
/s/ Phillip Frost, M.D., Individually and as Trustee
Issuer symbol
COCP
Transactions as of
04 Apr 2023
Net transactions value
+$2,000,001
Form type
4
Filing time
06 Apr 2023, 16:01:20 UTC
Previous filing
23 Mar 2023
Next filing
14 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COCP Common Stock Purchase $2,000,001 +1,015,229 +333% $1.97 1,319,838 04 Apr 2023 By Frost Gamma Investments Trust F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities were purchased in a private transaction with the Issuer.
F2 The amount of securities beneficially owned has been adjusted for the one-for-12 reverse stock split effective October 11, 2022.
F3 These securities are held by Frost Gamma Investments Trust, of which Phillip Frost, MD (the "Reporting Person") is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. The Reporting Person is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. The Reporting Person is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.